Clearstead Advisors’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$238K Sell
2,974
-6,167
-67% -$508K ﹤0.01% 944
2025
Q4
$779K Buy
9,141
+3,242
+55% +$266K 0.01% 536
2025
Q3
$459K Buy
5,899
+561
+11% +$43.8K 0.01% 656
2025
Q2
$417K Buy
5,338
+2,956
+124% +$220K 0.01% 657
2025
Q1
$173K Buy
2,382
+271
+13% +$19.4K ﹤0.01% 867
2024
Q4
$156K Sell
2,111
-516
-20% -$36.1K ﹤0.01% 917
2024
Q3
$173K Sell
2,627
-1,760
-40% -$128K ﹤0.01% 901
2024
Q2
$405K Sell
4,387
-1,366
-24% -$121K 0.01% 586
2024
Q1
$487K Sell
5,753
-405
-7% -$34K 0.02% 315
2023
Q4
$470K Sell
6,158
-8,174
-57% -$569K 0.02% 319
2023
Q3
$993K Buy
14,332
+8,709
+155% +$700K 0.03% 303
2023
Q2
$530K Hold
5,623
0.03% 284
2023
Q1
$465K Buy
5,623
+1,638
+41% +$129K 0.03% 275
2022
Q4
$297K Buy
3,985
+1,124
+39% +$86.6K 0.02% 331
2022
Q3
$236K Sell
2,861
-51
-2% -$4.91K 0.02% 346
2022
Q2
$277K Sell
2,912
-1,042
-26% -$108K 0.02% 331
2022
Q1
$465K Buy
3,954
+1,059
+37% +$119K 0.03% 276
2021
Q4
$375K Sell
2,895
-198
-6% -$23.1K 0.03% 293
2021
Q3
$350K Sell
3,093
-107
-3% -$12.2K 0.03% 289
2021
Q2
$331K Buy
3,200
+127
+4% +$12K 0.03% 277
2021
Q1
$257K Buy
3,073
+136
+5% +$11.5K 0.02% 300
2020
Q4
$268K Hold
2,937
0.02% 283
2020
Q3
$234K Buy
2,937
+450
+18% +$35.1K 0.03% 262
2020
Q2
$172K Hold
2,487
0.02% 288
2020
Q1
$156K Buy
+2,487
New +$179K 0.02% 267

Other funds holding EW

Clearstead Advisors's EW Position: Q1 2026 in Review

Clearstead Advisors reduced its Edwards Lifesciences (EW) stake by 67% in Q1 2026, selling an estimated $508K and leaving 2,974 shares worth $238K. The position accounts for ﹤0.01% of the portfolio, ranked #944.

Clearstead Advisors first reported a position in EW in Q1 2020 and has held it in 25 quarters since. The position peaked at $993K in Q3 2023. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • Clearstead Advisors held 2,974 shares of Edwards Lifesciences worth $238K as of Q1 2026.
  • Clearstead Advisors sold 6,167 Edwards Lifesciences shares in Q1 2026, an estimated $508K.
  • Edwards Lifesciences made up ﹤0.01% of Clearstead Advisors's portfolio in Q1 2026, its #944 holding.
  • Clearstead Advisors first reported a position in Edwards Lifesciences in Q1 2020 and has held it in 25 quarters since.
  • Clearstead Advisors's Edwards Lifesciences position peaked at $993K in Q3 2023.
  • 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Clearstead Advisors's 13F filing for Q1 2026, filed 6 May 2026.